Allergan CEO on Innovation and Blockbuster Biopharmaceuticals

The transcript discusses Allergan's strategic focus on therapeutic areas and innovation, emphasizing the importance of blockbusters while maintaining a broad spectrum of treatments. It highlights the strategic fit and benefits of the Allergan-AbbVie merger, including increased R&D scale and diversification. Allergan's open science model supports innovation by collaborating with smaller companies. The transcript also addresses M&A challenges and antitrust considerations, ensuring a clear pathway for the merger.

How does the speaker view the relationship between innovation and R&D in the pharmaceutical industry?

What approach has the company taken to foster innovation according to the text?

What challenges does the speaker mention regarding antitrust issues in large pharmaceutical deals?